AIM To assess the efficacy and safety of a Chinese herbal medicine (CHM), Xiangsha Liujunzi granules, in the treatment of patients with functional dyspepsia (FD). METHODS We performed a randomized, double-blind, place...AIM To assess the efficacy and safety of a Chinese herbal medicine (CHM), Xiangsha Liujunzi granules, in the treatment of patients with functional dyspepsia (FD). METHODS We performed a randomized, double-blind, placebo-controlled trial with patients from three centers. Two hundred and sixteen subjects diagnosed with FD according to ROME. criteria and confirmed by upper gastrointestinal endoscopy and spleen-deficiency and Qi-stagnation syndrome were selected to receive Xiangsha Liujunzi granules or placebo for 4 wk in a 2: 1 ratio by blocked randomization. The subjects also received follow-up after the 4-wk intervention. Herbal or placebo granules were dissolved in 300 mL of water. Participants in both groups were administered 130 mL (45 degrees C) three times a day. Participants were evaluated prior to and following 4 wk of the intervention in terms of changes in the postprandial discomfort severity scale (PDSS) score, clinical global impression (CGI) scale score, hospital anxiety and depression scale (HADS) score, traditional Chinese medicine symptoms score (SS), scores of various domains of the 36-item short form health survey (SF-36), gastric emptying (GE) and any observed adverse effects. RESULTS Compared with the placebo group, patients in the CHM group showed significant improvements in the scores of PDSS, HADS, SS, SF-36 and CGI scale (P < 0.05 or P < 0.01). They also showed the amelioration in the GE rates of the proximal stomach and distal stomach (P < 0.05 or P < 0.01). CONCLUSION Xiangsha Liujunzi granules offered significant symptomatic improvement in patients with FD.展开更多
Although irritable bowel syndrome(IBS) and inflammatory bowel disease(IBD) are clinically common diseases with unclear pathogenesis, both of them are related to the immune system. With progress in studies on their pat...Although irritable bowel syndrome(IBS) and inflammatory bowel disease(IBD) are clinically common diseases with unclear pathogenesis, both of them are related to the immune system. With progress in studies on their pathogenesis, the two diseases are currently believed to be associated with the presence of intestinal inflammation and intestinal mucosal immune disorder. In recent years, a new approach for the prevention and treatment of chronic intestinal disease is to protect the complete structure and normal immunity of the intestinal mucosal barrier during the treatment of intestinal diseases. However, traditional Chinese medicine(TCM) may have more advantages in regulating the imbalance of the intestinal immune microenvironment, as various single herbs and compounds of TCM have been investigated from the perspective of immune regulation. The use of TCM is prevalent in China. The effectiveness of these therapies appears to be supported by preliminary evidence and clinical experience, although the mechanisms that underlie these effects will require further research. In this paper, with common chronic bowel diseases including IBS, ulcerative colitis and Crohn's disease as the research objects, the relationship between TCM and immunity was explored from the perspectives of the pathogenesis of intestinal mucosal immune injury, the correlation between TCM syndromes and immune disorders, and TCM immune regulation. Moreover, the problems and limitations of the present study were pointed out, and several suggestions were proposed. The purpose of this article is to explore the potential mechanism of TCM on intestinal mucosal immunity in chronic intestinal diseases.展开更多
基金Supported by the Major State Basic Research Development Program of China(973 Program)No.2013CB531703+1 种基金National Nature Science Foundation of China,No.81503567 and No.81673853the China Postdoctoral Science Foundation,No.2015M1227 and No.2016T90195
文摘AIM To assess the efficacy and safety of a Chinese herbal medicine (CHM), Xiangsha Liujunzi granules, in the treatment of patients with functional dyspepsia (FD). METHODS We performed a randomized, double-blind, placebo-controlled trial with patients from three centers. Two hundred and sixteen subjects diagnosed with FD according to ROME. criteria and confirmed by upper gastrointestinal endoscopy and spleen-deficiency and Qi-stagnation syndrome were selected to receive Xiangsha Liujunzi granules or placebo for 4 wk in a 2: 1 ratio by blocked randomization. The subjects also received follow-up after the 4-wk intervention. Herbal or placebo granules were dissolved in 300 mL of water. Participants in both groups were administered 130 mL (45 degrees C) three times a day. Participants were evaluated prior to and following 4 wk of the intervention in terms of changes in the postprandial discomfort severity scale (PDSS) score, clinical global impression (CGI) scale score, hospital anxiety and depression scale (HADS) score, traditional Chinese medicine symptoms score (SS), scores of various domains of the 36-item short form health survey (SF-36), gastric emptying (GE) and any observed adverse effects. RESULTS Compared with the placebo group, patients in the CHM group showed significant improvements in the scores of PDSS, HADS, SS, SF-36 and CGI scale (P < 0.05 or P < 0.01). They also showed the amelioration in the GE rates of the proximal stomach and distal stomach (P < 0.05 or P < 0.01). CONCLUSION Xiangsha Liujunzi granules offered significant symptomatic improvement in patients with FD.
基金supported by Major State Basic Research Development Program of China (973 Program) (No.2013CB531703)the General Program of National Nature Science Foundation of China (No. 81373580, 81503567 and 81173209)the Visiting Scientist Program of China Academy of Chinese Medical Sciences (No. ZZ070801)
文摘Although irritable bowel syndrome(IBS) and inflammatory bowel disease(IBD) are clinically common diseases with unclear pathogenesis, both of them are related to the immune system. With progress in studies on their pathogenesis, the two diseases are currently believed to be associated with the presence of intestinal inflammation and intestinal mucosal immune disorder. In recent years, a new approach for the prevention and treatment of chronic intestinal disease is to protect the complete structure and normal immunity of the intestinal mucosal barrier during the treatment of intestinal diseases. However, traditional Chinese medicine(TCM) may have more advantages in regulating the imbalance of the intestinal immune microenvironment, as various single herbs and compounds of TCM have been investigated from the perspective of immune regulation. The use of TCM is prevalent in China. The effectiveness of these therapies appears to be supported by preliminary evidence and clinical experience, although the mechanisms that underlie these effects will require further research. In this paper, with common chronic bowel diseases including IBS, ulcerative colitis and Crohn's disease as the research objects, the relationship between TCM and immunity was explored from the perspectives of the pathogenesis of intestinal mucosal immune injury, the correlation between TCM syndromes and immune disorders, and TCM immune regulation. Moreover, the problems and limitations of the present study were pointed out, and several suggestions were proposed. The purpose of this article is to explore the potential mechanism of TCM on intestinal mucosal immunity in chronic intestinal diseases.
